28 million euros to save human lives
MULHOUSE, France– CellProthera, a biotech company which offers the most advanced cell therapy for regeneration of the damaged heart muscle after myocardial infarction, announces it has raised €8,300,000 from private investors in 2016. These funds, supplements the20 million€ raised during the previous rounds, and will enable CellProthera to pursue its scientific development, complete its Phase I/IIb clinical trial in Europe and prepare its Phase III in Europe and North America.
Matthieu de Kalbermatten nominated as CEO
MULHOUSE, France–(BUSINESS WIRE)–CellProthera, which offers the most advanced cell therapy for the regeneration of the damaged heart muscle after myocardial infarction, has changed its corporate governance and appointed Matthieu de Kalbermatten as CEO. He succeeds Jean-Claude Jelsch (currently Chairman of the Supervisory Board) and now manages the bio-tech firm alongside the Chairman, Professor Philippe Hénon.
A French start-up has designed and developed an automated device to culture heart stem cells. This might be an alternative to a heart transplant for 1 million patients in the main Western countries.
CellProthera, Pioneer in Cell Regenerative Therapy, Awarded the 2014 UBISTART Prize
A therapeutic approach to severe myocardial infarction, for which one million patients each year would be eligible
CD34+ cells and CD34+CD38- subset from mobilized blood show different patterns of adhesion molecules compared to those from steady-state blood, bone marrow and cord blood. H. Sovalat, E. Racadot, M. Ojeda, H. Lewandowski, V. Chabouté, Ph. Hénon. Journal of Hematotherapy and Stem Cell Research, 2003, 12:5, 473-489
Human embryonic or adult stem cells: Ethics and perspectives for tissue engineering Ph. Hénon dans : Tissue Engineering, Stem Cells and Gene Therapies, Advances in Experimental Medicine and Biology, Murat Elçin (Ed), Kluwer Academic / Plenum Publishers, New York, USA, 2003, 534, 27-45
Intracardiac reinjection of purified autologous blood CD34+ cells mobilized by G-CSF can significantly improve myocardial function in cardiac patients. Ph. Hénon, M. Ojeda, Y. Arkam, H. Sovalat, N. Bischoff, J.Ph. Monassier, I. Brink, Blood 2003; 102:11, 1208a
Long-term benefit of intracardiac delivery of autologous granulocyte–colony stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct. Pasquet S , Sovalat H , Hénon Ph , et al. Cytotherapy, vol. 11, N°8,